BusinessPhoto: Business StandardMankind Pharma to Acquire 70% Stake in Belgian Biotech for €48 Million
Mankind Pharma announced it will acquire a 70% stake in Belgium-based Armed Cell Therapeutics (ACTx) for €48 million (Rs 511 crore). This acquisition, via its Netherlands subsidiary, marks Mankind's entry into next-generation CAR-T cancer therapies and expands its global innovation-led pharmaceutical business. The deal provides access to advanced cell-therapy research targeting non-Hodgkin lymphoma and small-cell lung cancer, advancing Mankind's international presence.
Business Standard·




